Cellestia Biotech or how to successfully launch a university spin-off into a biotech company

About the event

Please register for this event through the event website.

i-net & LSNB Event: «Cellestia Biotech or how to successfully launch a university spin-off into a biotech company»

Cel­lestia Bio­tech was foun­ded in 2014 as a spin-off from the Swiss In­sti­tu­te for Ex­pe­ri­men­tal Can­cer Re­se­arch at EPFL, with its head­quar­ters in Basel and re­se­arch ope­ra­ti­ons in Lau­sanne. The focus of Cel­lestia Bio­tech lays on an­ti-can­cer drugs mo­du­la­ting the NOTCH pa­thway, with a novel, first-in-class, oral pan-NOTCH in­hi­bi­tor as lead com­pound. The com­pa­ny – which is ma­na­ged by a high-ca­li­bre team of aca­de­mic and in­dus­try pro­fes­sio­nals – is now suc­cess­ful­ly ad­van­cing the pro­ject from the re­se­arch to de­ve­lop­ment stage.

This i-net/LSNB event (Hal­le7 in Basel, Fe­bru­ary 23nd, 19:00; door opening 18:45) will have Mi­cha­el Bauer, CEO of Cel­lestia Bio­tech and an ex­pe­ri­en­ced in­dus­try pro­fes­sio­nal, tal­king about this story and sharing in­sights and learnings along the way, es­pe­cial­ly also fo­cus­sing on les­son lear­ned on the tran­si­ti­on from aca­de­mic re­se­arch to a drug de­ve­lop­ment com­pa­ny. Also at­ten­ding are Dirk Weber, CMO, and Ra­jwin­der Lehal, CSO of Cel­lestia Biotech.

After the event, there will be a net­wor­king Apéro.

CV Dr. Mi­cha­el Bauer
Mi­cha­el Bauer, Chief Exe­cu­ti­ve Of­fi­cer of Cel­lestia Bio­tech, is a se­ni­or drug de­ve­lop­ment pro­fes­sio­nal with over 18 years of ex­pe­ri­ence in the Life Sci­en­ces in­dus­try. He ser­ved in se­ni­or lea­dership po­si­ti­ons across di­sci­pli­nes such as cli­ni­cal and pre­cli­ni­cal drug de­ve­lop­ment, pro­ject & port­fo­lio ma­nage­ment, re­gu­la­to­ry af­fairs and me­ta­bo­lism re­se­arch. Most re­cent as­si­gn­ments were with No­var­tis Phar­ma AG, Trans­la­tio­nal Me­di­ci­ne On­co­lo­gy, working as Se­ni­or Glo­bal Pro­gram Ma­na­ger De­ve­lop­ment and Po­ly­phor Ltd., where he ser­ved as Head of Cli­ni­cal De­ve­lop­ment. Under his lea­dership, se­veral new on­co­lo­gy drugs were brought into cli­ni­cal de­ve­lop­ment and re­ached cli­ni­cal proof of con­cept. Mi­cha­el holds a Ph.D. in Bio­tech­no­lo­gy and M.​Sc. in Chemistry.